Facebook
X
LinkedIn
ForwardSteven Campbell, MD
Dr. Campbell obtained BS, MD and PhD degrees at The University of Chicago and then did a Urology Residency at Cleveland Clinic (1989-1995), followed by a fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center (1995-1996). Dr. Campbell’s primary interests have included renal cell carcinoma, bladder cancer, prostate cancer, tumor angiogenesis, and urology residency training. His background also includes American Foundation for Urological Diseases (AFUD) and Kimmel Research Scholarship Awards. He has served as Chair of the Exam Committee for the Society of Urologic Oncology and President for the Society of Pelvic Surgeons. Dr. Campbell was Chair for the AUA Guidelines Panel for Management of Localized Kidney Cancer (2017 and 2021), and was Co-Chair for the previous iteration of this in 2009. Dr. Campbell was Co-Editor of Renal Cell Carcinoma (BC Decker, 2009) and Editor of Renal Cell Carcinoma: Clinical Management (Humana Press, 2013) and 100 Questions and Answers about Kidney Cancer (Jones and Bartlett, 2008, 2012, 2015, 2018, and 2021). Dr. Campbell has also authored or co-authored “Malignant Renal Tumors” for Campbell/Walsh Urology for the past 6 editions (2000, 2005, 2010, 2015, 2019, and 2024). Dr. Campbell also served as a Urology Residency Program Director for 18 years, with his program consistently recognized as the top program in the US (2014-2024) based on reputation in the field.
Over the past decade Dr. Campbell’s academic work has focused on the role of PN and RN in the management of RCC, the determinants of functional recovery after PN, the survival implications of differences in renal function after renal cancer surgery, the use of neoadjuvant TKI’s to enable PN and optimize functional outcomes, and improved methods for prediction of new baseline GFR after renal cancer surgery. In 2019 Dr. Campbell received an AUA Distinguished Contribution Award for sentinel research in the field of urologic oncology, particularly in the area of renal neoplasia. In 2020 he received the Andrew C. Novick Award from the International Kidney Cancer Association for noteworthy research contributions and leadership in the field.
Over the past decade Dr. Campbell’s academic work has focused on the role of PN and RN in the management of RCC, the determinants of functional recovery after PN, the survival implications of differences in renal function after renal cancer surgery, the use of neoadjuvant TKI’s to enable PN and optimize functional outcomes, and improved methods for prediction of new baseline GFR after renal cancer surgery. In 2019 Dr. Campbell received an AUA Distinguished Contribution Award for sentinel research in the field of urologic oncology, particularly in the area of renal neoplasia. In 2020 he received the Andrew C. Novick Award from the International Kidney Cancer Association for noteworthy research contributions and leadership in the field.
Financial relationships
There are no financial relationships to disclose.